This series of 12 articles, consisting of 9 original articles and 3 reviews, is presented by
international leaders in translational cancer research. This series highlights the various …

Background: Clinical oncology trials in humans have major limitations, not the least of which
is the inability to treat a single tumor with multiple drugs simultaneously to identify the most …

Lung cancer is one of the most prevalent, fatal, and highly heterogeneous diseases that,
seriously threaten human health. Lung cancer is primarily caused by the aberrant …

According to the Special Report on Cancer Prevalence published by the Canadian Cancer
Society, Statistics Canada, and the Public Health Agency of Canada in November 2022 …

The pursuit of precision oncology heavily relies on large-scale genomic and
pharmacological data garnered from preclinical cancer model systems such as cell lines …

The prediction of anticancer drug response is crucial for achieving a more effective and
precise treatment of patients. Models based on the analysis of large cell line collections …

Although anti-cancer treatments have significantly advanced over the past decades,
obstacles to accomplishing successful treatment still exist. The occurrence of treatment …

The amount of “big” data generated in clinical oncology, whether from molecular, imaging,
pharmacological, or biological origin, brings novel challenges. To mine efficiently this source …

Recent advances in high-throughput technologies have facilitated the profiling of large
panels of cancer cell lines with responses measured for thousands of drugs. The …

Cancer treatments can be highly toxic and frequently only a subset of the patient population
will benefit from a given treatment. Tumour genetic makeup plays an important role in cancer …